Premature compared with late onset of coronary artery disease: Young patients show a severe defect in fibrinolytic response to venous occlusion

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 2, 2007, Pages 165-171

  Stefan Speidl, Walter ^a   Nikfardjam, Mariam ^a   Niessner, Alexander ^a   Jordanova, Nelli ^b   Zorn, Gerlinde ^a   Maurer, Gerald ^a   Schreiber, Wolfgang ^a   Wojta, Johann ^a   Huber, Kurt ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

Author keywords

Fibrinolysis; Premature coronary artery disease; Tissue type plasminogen activator

Indexed keywords

C REACTIVE PROTEIN; CELL ADHESION MOLECULE; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CELL ADHESION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HUMAN; MALE; MULTIVARIATE ANALYSIS; ONSET AGE; PREMATURITY; PRIORITY JOURNAL; ST SEGMENT ELEVATION; VEIN OCCLUSION;

ADULT; AGE OF ONSET; AGED; BIOLOGICAL MARKERS; CORONARY ARTERIOSCLEROSIS; FEMALE; FIBRINOLYSIS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; THROMBOPHILIA; TISSUE PLASMINOGEN ACTIVATOR; VENOUS THROMBOSIS;

EID: 33846925657     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328040bf87     Document Type: Article

References (32)

1. Margaglione M, Cappucci G, d'Addedda M, Colaizzo D, Giuliani N, Vecchione G, et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol 1998; 18:562-567.
2. Huber K. Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease. J Thromb Thrombolysis 2001; 11:183-193.
3. Doughty M, Mehta R, Bruckman D, Das S, Karavite D, Tsai T, et al. Acute myocardial infarction in the young - The University of Michigan experience. Am Heart J 2002; 143:56-62.
4. Imazio M, Bobbio M, Bergerone S, Barlera S, Maggioni AP. Clinical and epidemiological characteristics of juvenile myocardial infarction in Italy: the GISSI experience. G Ital Cardiol 1998; 28:505-512.
5. Choudhury L, Marsh JD. Myocardial infarction in young patients. Am J Med 1999; 107:254-261.
6. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-126.
7. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-979.
8. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99:237-242.
9. Speidl WS, Graf S, Hornykewycz S, Nikfardjam M, Niessner A, Zorn G, et al. High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. Am Heart J 2002; 144:449-455.
10. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 144:537-547.
11. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767-1772.
12. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351:88-92.
13. Li YH, Teng JK, Tsai WC, Tsai LM, Lin LJ, Guo HR, et al. Prognostic significance of elevated hemostatic markers in patients with acute myocardial infarction. J Am Coll Cardiol 1999; 33:1543-1548.
14. Huber K, Christ G, Wojta J, Gulba D. Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. Thromb Res 2001; 103 (Suppl 1):S7-S19.
15. Francis RB Jr, Kawanishi D, Baruch T, Mahrer P, Rahimtoola S, Feinstein DI. Impaired fibrinolysis in coronary artery disease. Am Heart J 1988; 115:776-780.
16. Nikfardjam M, Graf S, Beckmann R, Hornykewycz S, Koller-Strametz J, Binder BR. Fibrinolytic response to venous occlusion compared to physical stress test in young patients with coronary artery disease. Thromb Haemost 1999; 82 (Suppl 1):80-84.
17. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999; 100:1016-1030.
18. Robertson BR, Pandolfi M, Nilsson IM. 'Fibrinolytic capacity' in healthy volunteers at different ages as studied by standardized venous occlusion of arms and legs. Acta Med Scand 1972; 191:199-202.
19. Christ G, Graf S, Huber-Beckmann R, Zorn G, Lang I, Kneussi M, et al. Impairment of the plasmin activation system in primary pulmonary hypertension: evidence for gender differences. Thromb Haemost 2001; 86:557-562.
20. Huber K, Rosc D, Resch I, Schuster E, Glogar DH, Kaindl F, et al. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromb Haemost 1988; 60:372-376.
21. Wojta J, Turcu L, Wagner OF, Korninger C, Binder BR. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function usingmonoclonal anti-tissue-type plasminogen activator antibodies. J Lab Clin Med 1987; 109:665-671.
22. Carroll VA, Griffiths MR, Geiger M, Merlo C, Furlan M, Lammle B, et al. Plasma protein C inhibitor is elevated in survivors of myocardial infarction. Arterioscler Thromb Vasc Biol 1997; 17:114-118.
23. Wojta J, Holzer M, Hufnagl P, Christ G, Hoover RL, Binder BR, et al. Hyperthermia stimulates plasminogen activator inhibitor type 1 expression in human umbilical vein endothelial cells in vitro. Am J Pathol 1991; 139:911-919.
24. Wieczorek I, Ludlam CA, MacGregor I. Venous occlusion does not release von Willebrand factor, factor VIII or PAI-1 from endothelial cells - the importance of consensus on the use of correction factors for haemoconcentration. Thromb Haemost 1993; 69:91-93.
25. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials 1990; 11:116-128.
26. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313:1557-1563.
27. Malmberg K, Bavenholm P, Hamsten A. Clinical and biochemical factors associated with prognosis after myocardial infarction at a young age. J Am Coll Cardiol 1994; 24:592-599.
28. Speidl WS, Zeiner A, Nikfardjam M, Geppert A, Jordanova N, Niessner A. An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion. J Am Coll Cardiol 2005; 45:30-34.
29. Bogaty P, Poirier P, Simard S, Boyer L, Solymoss S, Dagenais GR. Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. Circulation 2001; 103:3062-3068.
30. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997; 43:52-58.
31. Kienast J, Thompson SG, Raskino C, Pelzer H, Fechtrup C, Ostermann H, et al. Prothrombin activation fragment 1+2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis. Thromb Haemost 1993; 70:550-553.
32. Goto S, Kawai Y, Handa S, Abe S, Takahashi E, Watanabe K, et al. Serial changes in plasma concentration of plasminogen activator inhibitor-1 before and serially after thrombolytic therapy for acute myocardial infarction. Cardiology 1993; 82:280-285.